Gadopiclenol in Contrast Enhanced MRI of the Prostate
Gadopiclenol (Elucirem): A New Gadolinium Based Contrast Agent With High Relaxivity for Increased Contrast and Improved Differentiation of Clinically Significant Prostate Cancer on Contrast Enhanced MRI: A Prospective Study.
Sponsor: Columbia University
A PHASE4 clinical study on Prostate Cancer, this trial is actively recruiting participants. The trial is conducted by Columbia University and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE4
Status: Suspended → Recruiting
-
Oct 2024 — Nov 2025 [monthly]
Suspended PHASE4
Status: Not Yet Recruiting → Suspended
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- Guerbet
For direct contact, visit the study record on ClinicalTrials.gov .